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Items for this week’s EPI Update include: 
• Coagulopathies Associated with Contaminated Synthetic 
Cannabinoids 
• Unusual resistance organisms widespread in the U.S. 
• Welcome new CADE employee 
• In the news: "Zombie-like" raccoons - Police probe calls about 
raccoons acting strangely in daytime 
• In the news: Shingles is nasty, and the new vaccine works well. Why 
do adults avoid shots? 
• In the news: U.S. infectious disease mortality, by county 
• Infographic: Containment strategy – Be on guard to contain the first 
spark 
• Meeting announcements and training opportunities 
 
Coagulopathies Associated with Contaminated Synthetic Cannabinoids 
As of Thursday, April 5, 2018, a total of 94 cases of severe coagulopathy and 
bleeding associated with synthetic cannabinoid use have been reported in five 
states (89 cases in Illinois, two cases in Indiana, one case in Missouri, one case 
in Wisconsin, and one case in Maryland). Two deaths have been reported in 
Illinois. The first case occurred in Illinois on March 7, 2018.  
 
These cases have used products containing synthetic cannabinoids (a.k.a. 
Spice, K2, legal weed, fake marijuana, synthetic marijuana, and synthetic THC). 
Synthetic cannabinoids can be smoked or sold as liquids to be vaporized and 
inhaled in e-cigarettes and other devices. The chemical brodifacoum, identified in 
biological samples from some patients, is widely used in pesticides (typically in 
rodent control) as a vitamin K antagonist anticoagulant poison. It is suspected 
that the brodifacoum was added to synthetic cannabinoid mixtures. 
 
Symptoms of severe coagulopathy include: easy bruising, bleeding from the nose 
or gums, coughing up blood, vomiting blood, blood in the urine or stool, severe 
menstrual bleeding and bleeding out of proportion to an injury. Laboratory tests 
have found the patients’ INRs to range from 6 to >20. A normal INR for a person 
not taking warfarin is around 1. 
 
No cases have been reported in Iowa. 
 
Healthcare providers are asked to take the following actions:  
• If a patient presents with significant bleeding and/or an elevated INR without 
a definitive cause, ask if synthetic cannabinoids were used in the last 
three months.  
• If a patient reports synthetic cannabinoid exposure or has evidence of 
bleeding, check the patient’s International Normalizing Ration (INR) prior 
to release. The INR has been elevated in some patients prior to clinical 
signs.  
• Advise patients that if they (and/or others they know) use synthetic 
cannabinoids and start experiencing severe bleeding or bruising, have 
someone take them to the hospital immediately or call 911. Advise 
patients to tell their healthcare providers about the possible link between 
symptoms and synthetic cannabinoid use.  
• To discuss treatment and management guidance for potential patients, 
please call the Iowa Poison Control Center at 800-222-1222.  
• For surveillance purposes, please report suspected cases to the Iowa 
Department of Public Health at 866-834-9671. 
 
Unusual resistance organisms widespread in the U.S. 
More than 23,000 Americans die each year from infections caused by organisms 
resistant to antibiotics. While antibiotic resistance (AR) threats vary nationwide, 
AR has been found in every state. And unusual resistance organisms, which are 
resistant to all or most antibiotics tested and are uncommon or carry special 
resistance genes, are constantly developing and spreading. Lab tests uncovered 
unusual resistance more than 200 times in 2017 in bacteria alone.  
 
Health Care Facilities are encouraged to: 
• Establish protocols to immediately notify the health care provider and 
infection control staff of unusual resistance.  
• When unusual resistance organisms are identified: 
o Place patients with unusual resistance on contact precautions, assess 
and enhance infection control, and work with public health to screen 
others.  
o Communicate about status when patients are transferred.  
o Continue infection control assessments and colonization screenings 
until spread is controlled.  
o Ask about any recent travel or health care to identify at-risk patients. 
 
For additional information visit https://www.cdc.gov/vitalsigns/containing-unusual-
resistance/ .  
 
 
Welcome new CADE employee 
Tyra Goss BSN, RN has recently joined the CADE team as the Healthcare 
Associated Infections Epidemiologist. Tyra has over 20 years of clinical and three 
years of infection prevention experience in the acute care setting. Tyra also has 
experience with employee health and education, and she has served as patient 
representative. Tyra has relocated from southeast Iowa, please help us welcome 
her to CADE! 
 
In the news: "Zombie-like" raccoons - Police probe calls about raccoons 




In the news: Shingles is nasty, and the new vaccine works well. Why do 








Infographic: Containment strategy – Be on guard to contain the first spark 
 
 
To view in full size, visit www.cdc.gov/vitalsigns/containing-unusual-
resistance/infographic.html#infographic.  
 
Meeting announcements and training opportunities 
Don’t forget to register for the 2018 Infection Prevention & Control Seminar 
coming up on May 1-2, 2018 at the Holiday Inn Des Moines – Airport/Conference 
Center. You can register online at centerforconferences.uiowa.edu/iowa-
infection-prevention-and-control-seminar.  
 
Have a healthy and happy week! 
Center for Acute Disease Epidemiology 
Iowa Department of Public Health 
800-362-2736 
